Antares Pharma, Inc. (NASDAQ:ATRS) Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Antares Pharma, Inc. (NASDAQ ATRS) traded down 2.33% during midday trading on Thursday, hitting $3.77. The stock had a trading volume of 2,947,662 shares. The stock has a 50-day moving average price of $3.10 and a 200 day moving average price of $2.96. The firm’s market cap is $589.65 million. Antares Pharma, Inc. has a 12-month low of $1.41 and a 12-month high of $3.97.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The business had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million. On average, equities analysts anticipate that Antares Pharma, Inc. will post ($0.11) earnings per share for the current fiscal year.

WARNING: “Insider Selling: Antares Pharma, Inc. (ATRS) Director Sells 30,000 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/05/insider-selling-antares-pharma-inc-atrs-director-sells-30000-shares-of-stock.html.

A number of research firms have recently issued reports on ATRS. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a research report on Sunday, September 10th. Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th. Vetr upgraded Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target for the company in a research report on Monday, July 24th. Finally, Chardan Capital began coverage on Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $4.34.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. purchased a new stake in Antares Pharma in the 2nd quarter worth approximately $119,000. Legal & General Group Plc purchased a new stake in Antares Pharma in the 2nd quarter worth approximately $120,000. MML Investors Services LLC grew its stake in Antares Pharma by 228.2% in the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 30,000 shares during the period. Credit Suisse AG purchased a new stake in Antares Pharma in the 1st quarter worth approximately $146,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Antares Pharma in the 2nd quarter worth approximately $174,000. 36.77% of the stock is owned by institutional investors and hedge funds.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.